Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "VAC 18193 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the VAC 18193 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the VAC 18193 for RSV.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAC 18193 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
Drug Summary
VAC 18193 is Janssen's investigational prophylactic RSV senior vaccine, which is being investigated to prevent RSV-mediated lower respiratory tract disease in adults aged 60 or older. The prophylactic RSV senior vaccine candidate leverages unique features of Janssen's adenovector platform (AdVac). The investigational vaccine contains the gene encoding for the fusion protein of the RSV virus as an antigen. The Company has planned submissions in US and Europe in 2022 for RSV in adult's patients.
VAC 18193 Analytical Perspective
In-depth VAC 18193 Market Assessment
This report provides a detailed market assessment of VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
VAC 18193 Clinical Assessment
The report provides the clinical trials information of VAC 18193 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAC 18193 dominance.
- Other emerging products for RSV are expected to give tough market competition to VAC 18193 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAC 18193 in RSV.
- Our in-depth analysis of the forecasted sales data of VAC 18193 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAC 18193 in RSV.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of VAC 18193?
- What is the clinical trial status of the study related to VAC 18193 in Respiratory syncytial virus (RSV) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAC 18193 development?
- What are the key designations that have been granted to VAC 18193 for RSV?
- What is the forecasted market scenario of VAC 18193 for RSV?
- What are the forecasted sales of VAC 18193 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to VAC 18193 for RSV?
- Which are the late-stage emerging therapies under development for the treatment of RSV?
Key Topics Covered:
1. Report Introduction
2. VAC 18193 Overview in RSV
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. VAC 18193 Market Assessment
5.1. Market Outlook of VAC 18193 in RSV
5.2. 7MM Analysis
5.2.1. Market Size of VAC 18193 in the 7MM for RSV
5.3. Country-wise Market Analysis
5.3.1. Market Size of VAC 18193 in the United States for RSV
5.3.2. Market Size of VAC 18193 in Germany for RSV
5.3.3. Market Size of VAC 18193 in France for RSV
5.3.4. Market Size of VAC 18193 in Italy for RSV
5.3.5. Market Size of VAC 18193 in Spain for RSV
5.3.6. Market Size of VAC 18193 in the United Kingdom for RSV
5.3.7. Market Size of VAC 18193 in Japan for RSV
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/ls8963
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
